|
|
 |
|
This exciting Internet webcast begins with Eric J. Feldman, MD, discussing the progress of CML therapy and continues with an overview by Neil P. Shah, MD, PhD, as he reviews what new therapies like dasatinib (Sprycel®) and nilotinib (Tasigna®) hold for CML patients. This program for CML patients, caregivers, and healthcare professionals is sponsored by The Leukemia & Lymphoma Society through an unrestricted educational grant from Novartis Oncology.
|
|
|
|
|
|
|
|
|
| Sponsored by: |
Supported by an unrestricted educational grant from:
|
|
|
|
|
Eric J. Feldman, MD
Neil P. Shah, MD, PhD
Eric J. Feldman, MD
Eric J. Feldman, MD
